Literature DB >> 17634239

N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.

Elin S Gray1, Penny L Moore, Ralph A Pantophlet, Lynn Morris.   

Abstract

The monoclonal antibody (MAb) 2G12 recognizes a cluster of high-mannose oligosaccharides on the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 and is one of a select group of MAbs with broad neutralizing activity. However, subtype C viruses are generally resistant to 2G12 neutralization. This has been attributed to the absence of a glycosylation site at position 295 in most subtype C gp120s, which instead is typically occupied by a Val residue. Here we show that N-linked glycans in addition to the one at position 295 are important in the formation of the 2G12 epitope in subtype C gp120. Introduction of the glycosylation site at position 295 into three subtype C molecular clones, Du151.2, COT9.6, and COT6.15, did increase 2G12 binding to all three mutagenized gp120s, but at various levels. The COT9-V295N mutant showed the strongest 2G12 binding and was the only mutant to become sensitive to 2G12 neutralization, although very high antibody concentrations were required. Introduction of a glycosylation site at position 448 into mutant COT6-V295N, which occurs naturally in COT9, resulted in a virus that was partially sensitive to 2G12. Interestingly, a glycosylation site at position 442, which is common among subtype C viruses, also contributed to the 2G12 epitope. The addition of this glycan increased virus neutralization sensitivity to 2G12, whereas its deletion conferred resistance. Collectively, our results indicate that the 2G12 binding site cannot readily be reconstituted on the envelopes of subtype C viruses, suggesting structural differences from other HIV subtypes in which the 2G12 epitope is naturally expressed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634239      PMCID: PMC2045459          DOI: 10.1128/JVI.01106-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.

Authors:  T B Geijtenbeek; D S Kwon; R Torensma; S J van Vliet; G C van Duijnhoven; J Middel; I L Cornelissen; H S Nottet; V N KewalRamani; D R Littman; C G Figdor; Y van Kooyk
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

2.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

5.  In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Authors:  Amapola Manrique; Peter Rusert; Beda Joos; Marek Fischer; Herbert Kuster; Christine Leemann; Barbara Niederöst; Rainer Weber; Gabriela Stiegler; Hermann Katinger; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

6.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.

Authors:  J P Moore; J Sodroski
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

7.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Authors:  Amandeep K Dhillon; Helen Donners; Ralph Pantophlet; Welkin E Johnson; Julie M Decker; George M Shaw; Fang-Hua Lee; Douglas D Richman; Robert W Doms; Guido Vanham; Dennis R Burton
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

8.  Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Authors:  E S Gray; P L Moore; I A Choge; J M Decker; F Bibollet-Ruche; H Li; N Leseka; F Treurnicht; K Mlisana; G M Shaw; S S Abdool Karim; C Williamson; L Morris
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

9.  Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120.

Authors:  S Gnanakaran; Dorothy Lang; Marcus Daniels; Tanmoy Bhattacharya; Cynthia A Derdeyn; Bette Korber
Journal:  J Virol       Date:  2006-12-13       Impact factor: 5.103

10.  Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.

Authors:  Elin Solomonovna Gray; Tammy Meyers; Glenda Gray; David Charles Montefiori; Lynn Morris
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

View more
  32 in total

1.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Anila Yasmeen; Gabriel Ozorowski; Eden P Go; Laura K Pritchard; Miklos Guttman; Thomas A Ketas; Christopher A Cottrell; Ian A Wilson; Rogier W Sanders; Albert Cupo; Max Crispin; Kelly K Lee; Heather Desaire; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

2.  The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.

Authors:  Antoine Chaillon; Martine Braibant; Thierry Moreau; Suzie Thenin; Alain Moreau; Brigitte Autran; Francis Barin
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

3.  UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.

Authors:  Hazel T Mufhandu; Elin S Gray; Maphuti C Madiga; Nancy Tumba; Kabamba B Alexandre; Thandeka Khoza; Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris; Makobetsa Khati
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Ishita Rahman; Peter Hraber; Rory T Coffey; Daiva Nevidomskyte; Ayush Giri; Mohammed Asmal; Svetlana Miljkovic; Marcus Daniels; James B Whitney; Brandon F Keele; Beatrice H Hahn; Bette T Korber; George M Shaw; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

5.  Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin.

Authors:  Kabamba B Alexandre; Elin S Gray; Bronwen E Lambson; Penny L Moore; Isaac A Choge; Koleka Mlisana; Salim S Abdool Karim; James McMahon; Barry O'Keefe; Rachel Chikwamba; Lynn Morris
Journal:  Virology       Date:  2010-04-13       Impact factor: 3.616

6.  HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.

Authors:  Maria J Duenas-Decamp; Paul R Clapham
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  A lectin isolated from bananas is a potent inhibitor of HIV replication.

Authors:  Michael D Swanson; Harry C Winter; Irwin J Goldstein; David M Markovitz
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

8.  Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.

Authors:  Milan Raska; Kazuo Takahashi; Lydie Czernekova; Katerina Zachova; Stacy Hall; Zina Moldoveanu; Matt C Elliott; Landon Wilson; Rhubell Brown; Dagmar Jancova; Stephen Barnes; Jana Vrbkova; Milan Tomana; Phillip D Smith; Jiri Mestecky; Matthew B Renfrow; Jan Novak
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

9.  R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.

Authors:  Nagadenahalli B Siddappa; Jennifer D Watkins; Klemens J Wassermann; Ruijiang Song; Wendy Wang; Victor G Kramer; Samir Lakhashe; Michael Santosuosso; Mark C Poznansky; Francis J Novembre; François Villinger; James G Else; David C Montefiori; Robert A Rasmussen; Ruth M Ruprecht
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

10.  Glycosylation site-specific analysis of clade C HIV-1 envelope proteins.

Authors:  Eden P Go; Qing Chang; Hua-Xin Liao; Laura L Sutherland; S Munir Alam; Barton F Haynes; Heather Desaire
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.